Casdin Capital, a private equity firm, led a $28m Series B round in Xcell Biosciences, a biotechnology company, with the participation from Dynamk Capital, Formic Ventures, Labcorp, HBM Genomics and Viking Global Investors. “This new financing is an important validation of our successful track record and unique position in supporting immunotherapy researchers with innovative technology platforms focused on improving the performance of cell and gene therapies," Brian S. Feth, Xcell Co-founder and CEO.